Vericel Corp (NASDAQ:VCEL)’s share price shot up 4.8% during trading on Tuesday . The company traded as high as $6.05 and last traded at $5.45. 667,800 shares traded hands during trading, an increase of 34% from the average session volume of 500,018 shares. The stock had previously closed at $5.20.

A number of research firms have recently commented on VCEL. BTIG Research set a $6.00 price objective on shares of Vericel and gave the stock a “buy” rating in a report on Monday, October 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $9.00 price objective on shares of Vericel in a report on Tuesday. Finally, ValuEngine downgraded shares of Vericel from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

The stock has a market cap of $195.31, a price-to-earnings ratio of -6.76 and a beta of 3.02. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. Vericel had a negative net margin of 45.11% and a negative return on equity of 265.45%. The firm had revenue of $14.26 million during the quarter. equities research analysts predict that Vericel Corp will post -0.6 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new position in Vericel during the 3rd quarter valued at about $235,000. Archon Capital Management LLC lifted its holdings in Vericel by 95.7% during the 3rd quarter. Archon Capital Management LLC now owns 2,617,004 shares of the biotechnology company’s stock valued at $15,702,000 after purchasing an additional 1,279,925 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Vericel during the 3rd quarter valued at about $328,000. EAM Investors LLC bought a new position in Vericel during the 3rd quarter valued at about $943,000. Finally, Perkins Capital Management Inc. lifted its holdings in Vericel by 118.4% during the 3rd quarter. Perkins Capital Management Inc. now owns 562,600 shares of the biotechnology company’s stock valued at $3,376,000 after purchasing an additional 305,000 shares during the last quarter. 33.12% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2018/01/04/vericel-vcel-shares-up-4-8.html.

Vericel Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.